MDxHealth (MDXH) to Release Quarterly Earnings on Thursday

MDxHealth (NASDAQ:MDXH) is expected to be announcing its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to post earnings of ($0.10) per share and revenue of $26.1440 million for the quarter. Investors can find conference call details on the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

MDxHealth (NASDAQ:MDXH) last issued its quarterly earnings results on Thursday, May 14th. The company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05). The firm had revenue of $23.90 million during the quarter, compared to analysts’ expectations of $30.89 million. On average, analysts expect MDxHealth to post $-1 EPS for the current fiscal year and $-0 EPS for the next fiscal year.

MDxHealth Stock Down 2.8%

MDxHealth stock opened at $0.44 on Wednesday. The stock’s 50 day moving average is $0.48 and its 200 day moving average is $1.84. The company has a market capitalization of $21.83 million, a P/E ratio of -0.68 and a beta of 1.42. MDxHealth has a twelve month low of $0.40 and a twelve month high of $5.33.

Analyst Upgrades and Downgrades

MDXH has been the topic of a number of recent research reports. William Blair cut MDxHealth from an “outperform” rating to a “market perform” rating in a research note on Thursday, May 14th. Wall Street Zen cut shares of MDxHealth from a “hold” rating to a “strong sell” rating in a research note on Saturday, May 16th. Lake Street Capital cut their price objective on shares of MDxHealth from $9.00 to $5.00 and set a “buy” rating on the stock in a research report on Thursday, May 14th. BTIG Research reduced their price objective on shares of MDxHealth from $7.00 to $4.00 and set a “buy” rating for the company in a research note on Thursday, May 14th. Finally, TD Cowen reaffirmed a “buy” rating and issued a $1.50 target price (down from $7.00) on shares of MDxHealth in a report on Thursday, May 14th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $3.50.

Institutional Investors Weigh In On MDxHealth

Several large investors have recently bought and sold shares of MDXH. Jefferies Financial Group Inc. bought a new position in MDxHealth during the 3rd quarter valued at about $53,000. Russell Investments Group Ltd. purchased a new stake in shares of MDxHealth during the 3rd quarter valued at about $461,000. Kennedy Capital Management LLC bought a new stake in shares of MDxHealth in the third quarter worth approximately $1,826,000. Panoramic Capital LLC bought a new stake in shares of MDxHealth in the third quarter worth approximately $721,000. Finally, Bank of America Corp DE raised its holdings in shares of MDxHealth by 5,164.0% during the third quarter. Bank of America Corp DE now owns 15,055 shares of the company’s stock valued at $70,000 after purchasing an additional 14,769 shares during the last quarter.

About MDxHealth

MDxHealth, headquartered in Mechelen, Belgium, with a U.S. presence in Newton, Massachusetts, is a molecular diagnostics company focused on improving the accuracy of cancer diagnosis and treatment decision making through epigenetic biomarker assays. The company specializes in developing and commercializing tests that detect DNA methylation changes associated with urological cancers, enabling more precise risk stratification and patient management.

MDxHealth’s lead product portfolio includes ConfirmMDx and SelectMDx.